Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma

Dan T. Vogl, Thomas G. Martin, Ravi Vij, Parameswaran Hari, Joseph R. Mikhael, David Siegel, Ka Lung Wu, Michel Delforge, Cristina Gasparetto

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences